Phototherapy Equipment Market Size & Share 2026-2035

Phototherapy Equipment Market Size

The phototherapy equipment market was valued at USD 702.3 million in 2025, is projected to reach USD 753.2 million in 2026, and is expected to expand at a 6.3% CAGR from 2026 to 2035, reaching USD 1.31 billion by 2035.

The phototherapy equipment market is evolving from a predominantly institutional equipment category toward a broader care-delivery platform shaped by LED replacement demand, home-use device availability, and the differing procurement economics of neonatal and dermatological care. Demand is sustained by the clinical necessity of light-based treatment, although adoption speed depends on capital budgets, reimbursement, regulatory pathways, and patient access.

Phototherapy Equipment Market Trends, Growth Drivers & GMI Forecast Outlook

Neonatal care requirements provide a stable foundation for equipment demand, while dermatology broadens the addressable treatment base and homecare changes where therapy is delivered. The forecast depends on LED replacement cycles, hospital-capacity additions, regulatory progress for portable formats, and the ability of suppliers to overcome affordability barriers in lower-resource settings.

Key Drivers

*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*

Neonatal phototherapy benefits from a procurement logic that differs from elective capital spending. Hospitals offering delivery and neonatal services require reliable treatment capacity, making equipment replacement and ward expansion recurring purchasing events. This favors systems that are easier to maintain, provide dependable irradiance, and can be deployed across both higher-acuity units and less specialized facilities.

Dermatology demand is increasingly shaped by the practical ability of patients to complete prescribed treatment regimens. Home-based delivery can reduce the friction associated with repeated clinic attendance and creates an incremental equipment channel rather than merely replacing a clinic installation. As providers consider patient convenience, utilization, and treatment continuity together, compact and user-manageable systems become more commercially relevant.

The technology transition is also changing replacement decisions. LED platforms reduce dependence on consumable lamp replacements and enable more precise wavelength delivery, strengthening their case in clinical evaluations focused on operating burden as well as upfront cost. Early clinical research into wearable neonatal treatment formats indicates that care models preserving caregiver contact can support future category expansion, although adoption will depend on broader validation and regulatory execution ^{[7]Bilihome BV / European Journal of Pediatrics. "First in-human pilot study of wearable phototherapy for neonatal hyperbilirubinaemia." springer.com}.

Key Restraints

*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*

In lower-resource settings, the equipment decision is constrained by more than clinical need. Procurement can depend on public-budget cycles, donor participation, local servicing capability, and the availability of trained personnel. These constraints can delay adoption of commercial systems even where neonatal care needs are acute, directing suppliers toward value-oriented configurations, distributor partnerships, and financing models.

Clinic-based dermatology also faces a utilization challenge: treatment efficacy does not automatically translate into completed treatment courses when travel and scheduling burdens accumulate. Evidence from a randomized comparison of home- and office-based narrowband UV-B treatment illustrates why channel design matters to adherence and, consequently, to the perceived need for additional facility-based capacity ^{[4]Gelfand JM et al. "Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis." jamanetwork.com}.

Novel form factors add a separate constraint. Wearable and homecare-adapted equipment must meet regulatory, safety, usability, and monitoring expectations that are less demanding for conventional fixed systems. Suppliers therefore face a commercialization sequence in which product design, clearance strategy, reimbursement positioning, and clinician confidence must develop together.

Phototherapy Equipment Market Segment Analysis

By Product Type

LED-Based equipment generated USD 386.3 million in 2025 and is projected to reach USD 824.0 million by 2035. LED-Based systems are becoming the preferred replacement platform because their spectral control, energy efficiency, and lower maintenance requirements align with hospital purchasing priorities. Their relevance spans neonatal wards seeking dependable blue-light output and dermatology settings that require repeatable narrowband treatment delivery.

Conventional (Fluorescent/UV) equipment represented 35.0% of revenue in 2025 and is expected to account for 23.0% by 2035. Conventional systems retain relevance where installed assets remain serviceable and capital expenditure is constrained. However, their commercial position weakens as providers weigh maintenance exposure, lamp availability, and the operational advantages of LED alternatives during scheduled equipment refreshes.

Fiberoptic equipment generated USD 70.2 million in 2025 and is expected to grow at a 10.1% CAGR (2026–2035). Fiberoptic formats support care models in which treatment can continue with less disruption to infant handling and caregiver interaction. This functionality differentiates the category from overhead systems and makes it particularly relevant where neonatal workflows emphasize parent-infant contact and treatment flexibility.

By Application

Neonatal Jaundice equipment generated USD 456.5 million in 2025 and is projected to reach USD 759.0 million by 2035. Neonatal jaundice remains the primary clinical anchor of the Phototherapy Equipment Market because treatment capacity is embedded in maternity and newborn-care infrastructure. Procurement is typically tied to ward readiness, device reliability, and the need to provide rapid treatment rather than to discretionary patient demand.

Skin Disease Treatment accounted for 30.0% of revenue in 2025 and is projected to expand at an 8.7% CAGR (2026–2035). Skin disease treatment is gaining momentum as dermatology practices adopt more flexible treatment pathways for psoriasis, vitiligo, atopic dermatitis, and related conditions. The segment benefits from rising acceptance of home-based protocols, while competition from systemic therapies encourages suppliers to demonstrate convenience, tolerability, and practical treatment access.

Other Applications generated USD 35.1 million in 2025 and are projected to reach USD 65.0 million by 2035. Other applications remain comparatively specialized, with adoption dependent on the maturation of clinical evidence and provider acceptance of additional light-based treatment uses. Their value lies in extending equipment utilization beyond core neonatal and dermatology workflows without displacing those established demand centers.

By Modality

Fixed systems generated USD 421.4 million in 2025 and are expected to account for 52.0% of revenue by 2035. Fixed equipment remains integral to high-throughput hospitals and dermatology departments because it supports standardized workflows, controlled treatment environments, and full-body applications. Its enduring role reflects institutional preference for durable systems that fit established clinical layouts and staff routines.

Mobile systems accounted for 32.0% of revenue in 2025 and are projected to generate USD 444.7 million by 2035. Mobile platforms offer care teams flexibility to shift equipment between bedsides, wards, and lower-footprint treatment areas. This improves asset utilization where patient volumes fluctuate or where facilities need to extend phototherapy access without committing to dedicated fixed installations.

Wearable systems generated USD 56.2 million in 2025 and are expected to grow at a 12.5% CAGR (2026–2035). Wearable formats address a distinct clinical and commercial need: delivering treatment with less separation between patient and caregiver or with less dependence on a dedicated treatment room. Their adoption path will be shaped by evidence, clearance progression, clinician training, and the ability to demonstrate safe use outside conventional care settings.

By End Use

Hospitals & Clinics accounted for 85.0% of revenue in 2025 and are projected to generate USD 967.9 million by 2035. Hospitals and clinics will remain the central purchasing channel because neonatal and dermatological phototherapy are deeply integrated into institutional care pathways. Large providers also offer suppliers a route to standardized procurement, service contracts, and recurring replacement opportunities, though approval cycles can lengthen sales timelines.

Homecare generated USD 105.3 million in 2025 and is projected to expand at a 12.4% CAGR (2026–2035). Homecare demand is advancing where clinical protocols, patient preference, and payer incentives support treatment beyond the facility. The channel favors compact, intuitive, and appropriately monitored equipment, creating a distinct product-development requirement rather than a simple redistribution of hospital-based demand.

Phototherapy Equipment Market Regional Analysis

North America Phototherapy Equipment Market Analysis

The North America Phototherapy Equipment Market generated USD 211.0 million in 2025 and is projected to reach USD 353.0 million by 2035. The region combines established neonatal infrastructure with mature dermatology practices and a growing homecare channel. Demand is supported by structured purchasing systems, installed-base replacement requirements, and a regulatory environment that gives manufacturers a defined route for device commercialization.

U.S.

The U.S. generated USD 190.0 million in 2025 and is projected to reach USD 314.0 million by 2035. The U.S. market is supported by broad hospital networks, specialist dermatology care, and a comparatively developed environment for prescription-led home phototherapy. Manufacturers must balance clinical-evidence requirements with payer and provider workflow expectations to capture demand across both institutional and decentralized settings.

Canada

Canada accounted for 3.0% of revenue in 2025 and is projected to grow at a 6.4% CAGR (2026–2035). Canada's publicly funded care environment supports continuing facility-based treatment, while provincial coverage decisions will influence the pace at which homecare formats scale. Suppliers with reliable distribution and service coverage are well positioned to address a market where procurement consistency can matter more than rapid equipment turnover.

Europe Phototherapy Equipment Market Analysis

Europe accounted for 20.1% of revenue in 2025 and is projected to represent 16.0% by 2035. Europe's market is underpinned by established dermatology practices, neonatal-care infrastructure, and a substantial base of conventional systems approaching replacement decisions. Regulatory and sustainability considerations are reinforcing interest in LED alternatives, although country-level reimbursement and procurement structures remain decisive.

Germany

Germany generated USD 35.0 million in 2025 and is projected to reach USD 52.0 million by 2035. Germany's specialist-care network and clinically oriented dermatology environment support demand for modernized treatment platforms. The market favors suppliers that can demonstrate dependable performance, service responsiveness, and compatibility with institutional reimbursement pathways.

UK

The UK accounted for 3.3% of revenue in 2025 and is projected to generate USD 34.0 million by 2035. The UK's demand is shaped by public-system purchasing discipline and established phototherapy services. Replacement opportunities depend on how hospital trusts prioritize equipment modernization alongside competing capital needs.

France

France generated USD 20.0 million in 2025 and is projected to grow at a 3.8% CAGR (2026–2035). France's market is supported by hospital-based dermatology and neonatal services, with purchasing decisions influenced by reimbursement structures and clinical standardization. Suppliers able to integrate service, training, and dependable device support can strengthen their position in this measured-growth environment.

Spain

Spain accounted for 1.7% of revenue in 2025 and is projected to represent 1.3% by 2035. Spain remains principally dependent on hospital-based phototherapy provision. Relative share pressure reflects the faster expansion of emerging markets rather than an absence of clinical need, making replacement demand and public procurement timing the central commercial considerations.

Italy

Italy generated USD 12.0 million in 2025 and is projected to reach USD 17.0 million by 2035. Italy offers opportunities linked to regional healthcare purchasing and ongoing modernization of dermatology and neonatal equipment. Market access requires navigating decentralized procurement practices and demonstrating practical value for public and private providers.

Netherlands

The Netherlands accounted for 1.4% of revenue in 2025 and is projected to grow at a 3.4% CAGR (2026–2035). The Netherlands has relevance beyond its market size because of its role in homecare-oriented phototherapy innovation. Product developers can use clinically engaged local partners to test care models that may later translate to other European systems.

Rest of Europe

Rest of Europe generated USD 29.0 million in 2025 and is projected to grow at a 4.7% CAGR (2026–2035). This group encompasses markets with varied reimbursement maturity and capital-investment capacity. Growth prospects are tied to healthcare modernization, the expansion of specialist services, and the gradual replacement of legacy equipment across hospital networks.

Asia Pacific Phototherapy Equipment Market Analysis

Asia Pacific accounted for 30.0% of revenue in 2025 and is projected to grow at a 7.7% CAGR (2026–2035). Asia Pacific combines large neonatal-care requirements with ongoing hospital construction, a growing dermatology treatment base, and increasingly capable regional manufacturing. The region's opportunity is not homogeneous: premium urban facilities prioritize advanced equipment, while many markets require products that meet clinical needs within constrained procurement budgets.

China

China generated USD 70.0 million in 2025 and is projected to reach USD 142.0 million by 2035. China benefits from the scale of its hospital system and from domestic production capabilities that broaden access to phototherapy equipment. Competition will be influenced by product quality, local distribution reach, and the ability of manufacturers to address both high-volume neonatal demand and dermatological treatment growth.

Japan

Japan accounted for 6.7% of revenue in 2025 and is projected to generate USD 82.0 million by 2035. Japan's mature healthcare setting supports systematic purchasing of neonatal and dermatology equipment. Clinical quality, reliability, and long-term service performance are central to supplier differentiation in a market with well-established domestic and international participants.

India

India generated USD 40.0 million in 2025 and is projected to grow at a 9.0% CAGR (2026–2035). India's growth is connected to expansion in maternity care, private hospital capacity, and the need to improve newborn-treatment availability. Commercial success will depend on suppliers' ability to combine durable product design with price points suitable for public and private procurement tiers.

South Korea

South Korea accounted for 3.6% of revenue in 2025 and is projected to account for 3.6% by 2035. South Korea is a relatively mature regional market with established dermatological care and local manufacturing capability. Its stable position favors suppliers that can differentiate through technology, connected workflows, and specialized applications rather than basic capacity expansion.

Australia

Australia generated USD 14.0 million in 2025 and is projected to reach USD 24.0 million by 2035. Australia's demand base reflects organized healthcare provision and consistent requirements for neonatal and dermatological treatment equipment. Its geographic dispersion also supports the commercial rationale for homecare and mobile formats that reduce travel dependence for patients.

Rest of Asia Pacific

Rest of Asia Pacific accounted for 2.1% of revenue in 2025 and is projected to grow at a 13.9% CAGR (2026–2035). This group presents the region's strongest expansion potential as newborn-care investment, hospital-capacity additions, and distributor networks develop. Realizing that potential will require affordable equipment, local training, and after-sales support capable of reaching facilities outside major metropolitan centers.

Latin America Phototherapy Equipment Market Analysis

Latin America generated USD 56.0 million in 2025 and is projected to account for 10.0% of revenue by 2035. Latin America's market is supported by demand from public and private hospital systems, but affordability and procurement volatility temper equipment adoption. Suppliers that provide cost-effective systems, dependable servicing, and flexible commercial arrangements are better positioned to convert healthcare-infrastructure investment into sustained demand.

Brazil

Brazil generated USD 28.9 million in 2025 and is projected to reach USD 66.5 million by 2035. Brazil is the principal regional market because its large public health system operates alongside an extensive private-provider network. Neonatal equipment demand provides stability, while growing dermatology services create opportunities for a broader mix of clinic and homecare offerings.

Mexico

Mexico accounted for 2.6% of revenue in 2025 and is projected to grow at an 8.4% CAGR (2026–2035). Mexico's opportunity is tied to hospital-network expansion and rising investment in neonatal care. Adoption outside major cities will depend on the availability of trained users, distributor coverage, and products designed for cost-sensitive institutional budgets.

Argentina

Argentina generated USD 5.6 million in 2025 and is projected to account for 1.0% by 2035. Argentina retains underlying clinical demand, although procurement conditions can be sensitive to broader economic constraints. Suppliers that maintain resilient local channels and service availability can better manage uneven capital-purchasing cycles.

Rest of Latin America

Rest of Latin America accounted for 0.5% of revenue in 2025 and is projected to grow at a 12.1% CAGR (2026–2035). The group offers early-stage opportunities as public health systems expand maternal, neonatal, and specialist-care capacity. Demand conversion will rely on practical financing and on equipment models suited to diverse facility capabilities.

Middle East & Africa Phototherapy Equipment Market Analysis

Middle East & Africa accounted for 11.8% of revenue in 2025 and is projected to generate USD 170.0 million by 2035. The region contains sharply different purchasing environments, from well-capitalized Gulf healthcare systems to markets facing acute equipment-access limitations. This divergence requires suppliers to deploy distinct approaches for premium hospital modernization and for broader access-oriented neonatal care.

Saudi Arabia

Saudi Arabia accounted for 3.6% of revenue in 2025 and is projected to generate USD 51.0 million by 2035. Saudi Arabia's hospital expansion and health-system modernization support demand for advanced neonatal and dermatology equipment. Large institutional projects favor suppliers able to provide documentation, training, service coverage, and dependable fulfillment at scale.

UAE

The UAE generated USD 19.9 million in 2025 and is projected to grow at a 6.9% CAGR (2026–2035). The UAE's advanced provider base supports demand for high-specification systems in maternity and dermatology settings. Commercial success is linked to premium positioning, regulatory readiness, and relationships with sophisticated hospital groups.

South Africa

South Africa generated USD 12.0 million in 2025 and is projected to account for 1.4% by 2035. South Africa's established private healthcare sector provides a more accessible commercial foundation than many neighboring markets. Broader adoption, however, depends on strengthening equipment availability and service capability across public facilities.

Rest of MEA

Rest of MEA accounted for 3.7% of revenue in 2025 and is projected to grow at an 8.9% CAGR (2026–2035). The market combines substantial unmet clinical need with constrained purchasing power and fragmented procurement. Supplier strategies must therefore balance commercial distribution with partnerships that improve access, local maintenance, and clinician confidence in the use of modern phototherapy equipment.

Phototherapy Equipment Market Share & Competitive Landscape

The Phototherapy Equipment Market share structure is moderately fragmented, with the top five companies collectively accounting for approximately 29.5% in 2025. Competition is shaped by clinical portfolio breadth, regulatory approvals, hospital relationships, manufacturing efficiency, local service capability, and the ability to address both neonatal and dermatological treatment settings.

GE HealthCare held approximately 10.7% of market share in 2025. GE HealthCare's position reflects the strength of its hospital relationships and its ability to offer neonatal-care solutions through established procurement channels. Its scale supports participation in high-value institutional tenders, where supplier reliability, clinical familiarity, and after-sales support can be as important as device specifications.

Natus Medical, under ArchiMed ownership, held approximately 8.8% of market share in 2025. Natus Medical retains a focused neonatal-care presence and benefits from a specialized clinical heritage. Its competitive position depends on maintaining product innovation and channel reach while competing against diversified medical-technology suppliers and value-oriented regional manufacturers.

Philips held approximately 3.6% of market share in 2025. Philips competes through its neonatal-care capabilities and the potential to position phototherapy systems within broader hospital workflows. Integration with connected-care environments can be strategically relevant where providers seek fewer vendors and more coordinated equipment ecosystems.

Regional and emerging manufacturers including Atom Medical, Neotech, Phoenix, Narang Medical Limited, David Medical, Ibis Medical, Medi Waves, Okuman, Phothera, SolRx, and UVBioTek contribute to competitive intensity by serving specialized clinical requirements, regional procurement systems, and homecare demand. Their influence is particularly visible where localized distribution, lower-cost product design, or application-specific expertise can outweigh the scale advantages of larger global participants.

Recent Industry Developments

In May 2025, the U.S. Food and Drug Administration cleared Gerium Medical's BiliWrap neonatal phototherapy unit through the 510(k) pathway, adding a new regulated product to the neonatal device category ^{[5]FDA / Gerium Medical, Ltd. "510(k) K243372 — BiliWrap Neonatal Phototherapy Unit." fda.gov}. The clearance highlights continued supplier activity around neonatal phototherapy formats and reinforces the importance of regulatory execution for product commercialization.

In May 2025, Phlecs received an OP-Zuid grant to support development of a next-generation full-body blue-light home device for eczema treatment ^{[6]Phlecs BV. "Phlecs announces a clinical breakthrough in treatment of eczema and secures a grant to develop its next-generation device." phlecs.com}. The initiative illustrates ongoing investment in home-oriented dermatology equipment and the commercial interest in alternatives that may reduce dependence on facility-based phototherapy.